[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555676":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":70,"collaborators":73,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":30,"eligibilityCriteria":82,"healthyVolunteers":79,"sex":83,"minAge":84,"maxAge":30,"enrollmentInfo":85,"targetDuration":30,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":30,"overallStatus":51,"whyStopped":30,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University of California, San Diego","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"CoQ10 Arm 1","ACTIVE_COMPARATOR","PharmaNord Ubiquinone 100mg\u002F1x day",[13],"Drug: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg",{"label":15,"type":10,"description":16,"interventionNames":17},"CoQ10 Arm 2","PharmaNord Ubiquinone 100mg\u002F3x day",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo Arm","PLACEBO_COMPARATOR","Placebo (made by PharmaNord, matches active treatment)",[23],"Drug: PharmaNord Placebo",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","PharmaNord Bio-Quinone Active CoQ10 Gold 100mg","Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day.\n\nBecause of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option \"drug\" was chosen as the closest permissible option.",[9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"PharmaNord Placebo","Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.\n\nBecause of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option \"drug\" was chosen as the closest permissible option.",[19],{"type":26,"name":27,"description":36,"armGroupLabels":37,"otherNames":30},"Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.\n\nBecause of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option \"drug\" was chosen as the closest permissible option.",[15],[39],{"name":40,"affiliation":5,"role":41},"Beatrice A Golomb, MD, PhD","PRINCIPAL_INVESTIGATOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":30,"email":47},"Janis B Ritchie, BSN","CONTACT","858-558-4950","jbritchie@ucsd.edu",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"UC San Diego","RECRUITING","La Jolla","California","92093","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-117.2742,32.84727,{"lat":61,"lon":60},[64,68],{"name":65,"role":45,"phone":46,"phoneExt":66,"email":67},"Janis B. Ritchie, BSN","203","golombresearch@ucsd.edu",{"name":69,"role":41,"phone":30,"phoneExt":30,"email":30},"Beatrice A. Golomb, MD, PhD",{"type":41,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Beatrice Golomb","Professor of Medicine",[74],{"name":75,"class":76},"United States Department of Defense","FED","100555676","phase-3-coenzyme-q10-for-gulf-war-illness-a-replication-study-100555676",false,"NCT06515184","Coenzyme Q10 for Gulf War Illness: A Replication Study","Inclusion Criteria:\n\n* Meets both CDC and Kansas deployment and symptom inclusion criteria.\n* Does not have a disqualifying condition.\n* Able to travel to a local Quest facility for study blood draws.\n* Adequate internet access to allow ZoomPro visit participation and remote survey completion.\n* Health prior to the Gulf War rated as \"very good\" or \"excellent\" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms).\n* Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation.\n\nExclusion Criteria:\n\n* Participating in another clinical trial.\n* Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use.\n* On Coumadin\u002F warfarin.\n* Unable to participate for the required duration of the study.","ALL","50 Years",{"count":86,"type":87},192,"ESTIMATED","INTERVENTIONAL",[90],"PHASE3","The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.",[93,94,95],"Gulf War Syndrome","Persian Gulf Syndrome","Mitochondrial Disorder, Respiratory Chain","2026-04-27",{"date":98,"type":99},"2026-05-01","ACTUAL",{"date":101,"type":99},"2024-09-13",{"date":103,"type":87},"2027-12",{"name":5,"class":6},1]